Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis
Authors:
Open Access
- 19 April 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1386386
Abstract
Background: This retrospective observational cohort study aimed to evaluate whether tenecteplase’s use for acute ischemic stroke (AIS) has time management advantages and clinical benefits.Methods: 144 AIS patients treated with alteplase and 120 with tenecteplase were included. We compared baseline clinical characteristics, key reperfusion therapy time indices [onset-to-treatment time (OTT), door-to-needle time (DNT), and door-to-puncture time (DPT)] and clinical outcomes (24-h post-thrombolysis NIHSS improvement, and intracranial hemorrhage incidence) between the groups using univariate analysis. We assessed hospital stay durations and used binary logistic regression to examine tenecteplase’s association with DNT and DPT target times, NIHSS improvement, and intracranial hemorrhage.Results: Baseline characteristics showed no significant differences except hyperlipidemia and atrial fibrillation. OTT (133 vs. 163.72, p = 0.001), DNT (36.5 vs. 50, p < 0.001) and DPT (117 vs. 193, p = 0.002) were significantly faster in the tenecteplase group. The rates of DNT ≤ 45 min (65.83% vs. 40.44%, p < 0.001) and DPT ≤ 120 min (59.09% vs. 13.79%, p = 0.001) were significantly higher in the tenecteplase group. Tenecteplase was an independent predictor of achieving target DNT (OR 2.951, 95% CI 1.732–5.030; p < 0.001) and DPT (OR 7.867, 95% CI 1.290–47.991; p = 0.025). Clinically, the proportion NIHSS improvement 24 h post-thrombolysis was higher in the tenecteplase group (64.17% vs. 50%, p = 0.024). No significant differences were observed in symptomatic intracranial hemorrhage (sICH) or any intracranial hemorrhage (ICH). Patients receiving tenecteplase had shorter hospital stays (6 vs. 8 days, p < 0.001). Tenecteplase was an independent predictor of NIHSS improvement at 24 h (OR 1.715, 95% CI 1.011–2.908; p = 0.045). There was no significant association between thrombolytic choice and sICH or any ICH.Conclusion: Tenecteplase significantly reduced DNT and DPT. It was associated with early neurological function improvement (at 24 h), without compromising safety compared to alteplase. The findings support tenecteplase’s application in AIS.Keywords
This publication has 35 references indexed in Scilit:
- Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic StrokeJAMA Neurology, 2023
- Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trialThe Lancet, 2022
- NIHSS 24 h After Mechanical Thrombectomy Predicts 90-Day Functional OutcomeClinical Neuroradiology, 2021
- Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical PracticeJAMA, 2019
- Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trialsThe Lancet, 2016
- Intravenous tenecteplase in acute ischemic stroke: an updated reviewJournal of Neurology, 2013
- Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic StrokeJAMA, 2013
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trialThe Lancet, 2006
- A double-blind multicenter comparison of the efficacy and safety ofsaruplase andurokinase in thetreatment ofacutemyocardialinfarction: Report of the SUTAMI study groupJournal of Thrombosis and Thrombolysis, 1995